Myristoylation is the approach that was used to develop detemir insulin (Levemir®, Novo Nordisk), an analog of human insulin with a half-life of 7–8 h, which is commonly used in the management of T2DM in the clinic. Here, INS is linked to type 2 diabetes mellitus.